Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate

Daniel Goodman; Eric Pamer; Ann Jakubowski; Carol Morris; Kent Sepkowitz

doi:10.1086/341305

Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate

Clin Infect Dis. 2002 Aug 1;35(3):E35-6. doi: 10.1086/341305. Epub 2002 Jun 27.

Authors

Daniel Goodman¹, Eric Pamer, Ann Jakubowski, Carol Morris, Kent Sepkowitz

Affiliation

¹ Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA. goodmand@mskcc.org

PMID: 12115115
DOI: 10.1086/341305

Abstract

We report a case of invasive trichosporonosis due to Trichosporon beigelii originating in the left wrist of a bone marrow transplant recipient who was receiving caspofungin acetate as prophylaxis against invasive Aspergillus infection. While the patient's neutrophil count was recovering, treatment with fluconazole and amphotericin B lipid complex resulted in a complete clinical response.

Publication types

Case Reports

MeSH terms

Adult
Amphotericin B / therapeutic use*
Anti-Bacterial Agents / therapeutic use*
Antifungal Agents / therapeutic use*
Aspergillosis / prevention & control
Bone Marrow Transplantation
Caspofungin
Chemoprevention
Drug Therapy, Combination
Echinocandins
Fluconazole / therapeutic use*
Humans
Lipopeptides
Male
Mycoses / drug therapy*
Opportunistic Infections / drug therapy
Peptides*
Peptides, Cyclic*
Trichosporon* / drug effects

Substances

Anti-Bacterial Agents
Antifungal Agents
Echinocandins
Lipopeptides
Peptides
Peptides, Cyclic
Amphotericin B
Fluconazole
Caspofungin